Skip to main content
Top
Published in: Endocrine Pathology 1/2015

01-03-2015

Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics

Authors: James A. Balogun, Eric Monsalves, Kyle Juraschka, Kashif Parvez, Walter Kucharczyk, Ozgur Mete, Fred Gentili, Gelareh Zadeh

Published in: Endocrine Pathology | Issue 1/2015

Login to get access

Abstract

The aim of the study was to establish if the null cell adenoma (NCA) forms a distinct subgroup with unique clinicopathological characteristics within the nonfunctioning pituitary adenoma group particularly in relation to the silent gonadotroph adenomas (SGAs). We identified 31 patients with the pathological diagnosis of NCA verified by routine histology and immunohistochemistry with distinct differentiation from SGAs by an established negative testing for SF-1 at the Toronto Western Hospital between December 2004 and August 2010. We reviewed their demographic data, clinical features, magnetic resonance imaging, and the histologic variables: MIB-1, FGFR4, and P27. We compared these to 63 SGAs identified within the same period. All the NCAs were macroadenomas with diameter ranging from 15—57 mm and tumor volumes between 1.95–53.5 mm3. Preoperative cavernous sinus tumor growth was able to predict the presence of a residual after surgery (p = 0.023). Furthermore, preoperative cavernous sinus extension (p = 0.002) and negative P27 expression (p = 0.035) were able to independently predict the subsequent growth of the postoperative tumor residual. Comparing the NCA to SGA, we found that MIB-1 was higher in NCA (mean ± SD = 3.43 ± 2.76 %) compared to SGAs (mean ± SD = 2.49 ± 1.41 %) (p = 0.044). The preoperative and postoperative tumor volume doubling times (TVDTs) displayed a negative correlation in the SGA (r = −0.855, p = 0.002) while in the NCA, a positive correlation was evident (r = 0.718, p = 0.029). Our study suggests that the NCAs are a distinct group with differing behavioral characteristics from the SGAs. It also appears that the finding of cavernous sinus extension on preoperative imaging and a negative P27 expression on immunohistochemistry in NCAs may be valuable tools in predicting residual tumor growth which may impact on postoperative care.
Literature
1.
go back to reference Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annual review of pathology 4: 97–126CrossRefPubMed Asa SL, Ezzat S (2009) The pathogenesis of pituitary tumors. Annual review of pathology 4: 97–126CrossRefPubMed
2.
go back to reference Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Practice & Research Clinical Endocrinology & Metabolism 23: 625–638CrossRef Greenman Y, Stern N (2009) Non-functioning pituitary adenomas. Best Practice & Research Clinical Endocrinology & Metabolism 23: 625–638CrossRef
3.
go back to reference Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapcer Z, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER (2006) Pathobiology of Pituitary Adenomas and Carcinomas. Neurosurgery 59: 341–353CrossRefPubMed Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapcer Z, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER (2006) Pathobiology of Pituitary Adenomas and Carcinomas. Neurosurgery 59: 341–353CrossRefPubMed
4.
go back to reference Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM (2007) Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 45: 72–77PubMed Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM (2007) Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases. Folia neuropathologica/Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences 45: 72–77PubMed
5.
go back to reference Bujawansa S, Thondam SK, Steele C, Cuthbertson DJ, Gilkes CE, Noonan C, Bleaney CW, Macfarlane IA, Javadpour M, Daousi C (2014) Presentation, management and outcomes in acute pituitary apoplexy: a large single-centre experience from the United Kingdom. Clinical endocrinology 80: 419–424CrossRefPubMed Bujawansa S, Thondam SK, Steele C, Cuthbertson DJ, Gilkes CE, Noonan C, Bleaney CW, Macfarlane IA, Javadpour M, Daousi C (2014) Presentation, management and outcomes in acute pituitary apoplexy: a large single-centre experience from the United Kingdom. Clinical endocrinology 80: 419–424CrossRefPubMed
6.
go back to reference Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain pathology (Zurich, Switzerland) 22: 443–453 Mete O, Asa SL (2012) Clinicopathological correlations in pituitary adenomas. Brain pathology (Zurich, Switzerland) 22: 443–453
8.
go back to reference Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know? Archives of pathology & laboratory medicine 132: 1231–1240 Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know? Archives of pathology & laboratory medicine 132: 1231–1240
9.
go back to reference Miller BA, Rutledge WC, Ioachimescu AG, Oyesiku NM (2012) Management of large aggressive nonfunctional pituitary tumors: experimental medical options when surgery and radiation fail. Neurosurg Clin N Am 23: 587–594CrossRefPubMed Miller BA, Rutledge WC, Ioachimescu AG, Oyesiku NM (2012) Management of large aggressive nonfunctional pituitary tumors: experimental medical options when surgery and radiation fail. Neurosurg Clin N Am 23: 587–594CrossRefPubMed
10.
go back to reference Alahmadi H, Lee D, Wilson JR, Hayhurst C, Mete O, Gentili F, Asa SL, Zadeh G (2012) Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien) 154: 1493–1498CrossRef Alahmadi H, Lee D, Wilson JR, Hayhurst C, Mete O, Gentili F, Asa SL, Zadeh G (2012) Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien) 154: 1493–1498CrossRef
11.
go back to reference Chen L, White WL, Spetzler RF, Xu B (2011) A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome. Journal of neuro-oncology 102: 129–138CrossRefPubMed Chen L, White WL, Spetzler RF, Xu B (2011) A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome. Journal of neuro-oncology 102: 129–138CrossRefPubMed
12.
go back to reference Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. The Journal of clinical endocrinology and metabolism 97: 1745–1751CrossRefPubMed Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. The Journal of clinical endocrinology and metabolism 97: 1745–1751CrossRefPubMed
13.
go back to reference Monsalves E, Larjani S, Loyola Godoy B, Juraschka K, Carvalho F, Kucharczyk W, Kulkarni A, Mete O, Gentili F, Ezzat S, Zadeh G (2014) Growth patterns of pituitary adenomas and histopathological correlates. The Journal of clinical endocrinology and metabolism: jc20133054 Monsalves E, Larjani S, Loyola Godoy B, Juraschka K, Carvalho F, Kucharczyk W, Kulkarni A, Mete O, Gentili F, Ezzat S, Zadeh G (2014) Growth patterns of pituitary adenomas and histopathological correlates. The Journal of clinical endocrinology and metabolism: jc20133054
14.
go back to reference Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610–617; discussion 617–618CrossRefPubMed Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610–617; discussion 617–618CrossRefPubMed
15.
go back to reference Kovacs K, Horvath E, Ryan N, Ezrin C (1980) Null cell adenoma of the human pituitary. Virchows Archiv A, Pathological anatomy and histology 387: 165–174CrossRefPubMed Kovacs K, Horvath E, Ryan N, Ezrin C (1980) Null cell adenoma of the human pituitary. Virchows Archiv A, Pathological anatomy and histology 387: 165–174CrossRefPubMed
16.
go back to reference Gittoes NJ (1998) Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. The Journal of endocrinology 157: 177–186CrossRefPubMed Gittoes NJ (1998) Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. The Journal of endocrinology 157: 177–186CrossRefPubMed
17.
go back to reference Holm R (1995) Null cell adenomas and oncocytomas of the pituitary gland. Pathology, research and practice 191: 348–352CrossRefPubMed Holm R (1995) Null cell adenomas and oncocytomas of the pituitary gland. Pathology, research and practice 191: 348–352CrossRefPubMed
18.
go back to reference Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocrine reviews 19: 798–827PubMed Asa SL, Ezzat S (1998) The cytogenesis and pathogenesis of pituitary adenomas. Endocrine reviews 19: 798–827PubMed
19.
go back to reference Yamada S, Asa SL, Kovacs K (1988) Oncocytomas and null cell adenomas of the human pituitary: morphometric and in vitro functional comparison. Virchows Archiv A, Pathological anatomy and histopathology 413: 333–339CrossRefPubMed Yamada S, Asa SL, Kovacs K (1988) Oncocytomas and null cell adenomas of the human pituitary: morphometric and in vitro functional comparison. Virchows Archiv A, Pathological anatomy and histopathology 413: 333–339CrossRefPubMed
20.
go back to reference Sano T, Yamada S (1994) Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathology international 44: 697–703CrossRefPubMed Sano T, Yamada S (1994) Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathology international 44: 697–703CrossRefPubMed
21.
go back to reference Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta neuropathologica 111: 1–7CrossRefPubMed Al-Shraim M, Asa SL (2006) The 2004 World Health Organization classification of pituitary tumors: what is new? Acta neuropathologica 111: 1–7CrossRefPubMed
22.
go back to reference Young WF, Jr., Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV (1996) Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clinic proceedings 71: 649–656CrossRefPubMed Young WF, Jr., Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV (1996) Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clinic proceedings 71: 649–656CrossRefPubMed
23.
go back to reference Yamada S, Kovacs K, Horvath E, Aiba T (1991) Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age. Journal of neurosurgery 75: 902–905CrossRefPubMed Yamada S, Kovacs K, Horvath E, Aiba T (1991) Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age. Journal of neurosurgery 75: 902–905CrossRefPubMed
24.
go back to reference Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. Journal of neurosurgery 108: 525–532CrossRefPubMed Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. Journal of neurosurgery 108: 525–532CrossRefPubMed
25.
go back to reference Greenman Y, Ouaknine G, Veshchev I, Reider G, II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical endocrinology 58: 763–769CrossRefPubMed Greenman Y, Ouaknine G, Veshchev I, Reider G, II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical endocrinology 58: 763–769CrossRefPubMed
26.
go back to reference Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European journal of endocrinology/European Federation of Endocrine Societies 163: 193–200CrossRefPubMed Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European journal of endocrinology/European Federation of Endocrine Societies 163: 193–200CrossRefPubMed
27.
go back to reference Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61: 580–584; discussion 584–585CrossRefPubMed Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61: 580–584; discussion 584–585CrossRefPubMed
28.
go back to reference Steno A, Bocko J, Rychly B, Chorvath M, Celec P, Fabian M, Belan V, Steno J (2014) Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir (Wien) 156: 451–461CrossRef Steno A, Bocko J, Rychly B, Chorvath M, Celec P, Fabian M, Belan V, Steno J (2014) Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir (Wien) 156: 451–461CrossRef
29.
go back to reference Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. Journal of neurosurgery 111: 563–571CrossRefPubMed Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. Journal of neurosurgery 111: 563–571CrossRefPubMed
30.
go back to reference Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurologia medico-chirurgica 52: 563–569CrossRefPubMed Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurologia medico-chirurgica 52: 563–569CrossRefPubMed
31.
go back to reference Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 49: 1193–1194CrossRef Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 49: 1193–1194CrossRef
32.
go back to reference Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T (1997) MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139: 426–431; discussion 431–422CrossRef Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T (1997) MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139: 426–431; discussion 431–422CrossRef
33.
go back to reference Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. Journal of neurosurgery 99: 674–679CrossRefPubMed Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. Journal of neurosurgery 99: 674–679CrossRefPubMed
34.
go back to reference Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138: 1449–1455CrossRef Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 138: 1449–1455CrossRef
35.
go back to reference Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47: 1313–1318; discussion 1318–1319CrossRefPubMed Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M (2000) Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results. Neurosurgery 47: 1313–1318; discussion 1318–1319CrossRefPubMed
36.
go back to reference Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. European journal of endocrinology/European Federation of Endocrine Societies 157: 141–147CrossRefPubMed Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. European journal of endocrinology/European Federation of Endocrine Societies 157: 141–147CrossRefPubMed
37.
go back to reference Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, Schulte HM (1999) Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. European journal of endocrinology/European Federation of Endocrine Societies 140: 250–255CrossRefPubMed Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, Schulte HM (1999) Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. European journal of endocrinology/European Federation of Endocrine Societies 140: 250–255CrossRefPubMed
38.
go back to reference Zhao D, Tomono Y, Nose T (1999) Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141: 187–192CrossRef Zhao D, Tomono Y, Nose T (1999) Expression of P27kip1 and Ki-67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir (Wien) 141: 187–192CrossRef
39.
go back to reference Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB (2002) Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. The Journal of clinical endocrinology and metabolism 87: 2635–2643CrossRefPubMed Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB (2002) Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. The Journal of clinical endocrinology and metabolism 87: 2635–2643CrossRefPubMed
40.
go back to reference Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz HG, Hainfellner J, Knosp E (2004) Expression of cell proliferation markers in pituitary adenomas—correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien) 146: 831–839 Wolfsberger S, Wunderer J, Zachenhofer I, Czech T, Bocher-Schwarz HG, Hainfellner J, Knosp E (2004) Expression of cell proliferation markers in pituitary adenomas—correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha. Acta Neurochir (Wien) 146: 831–839
Metadata
Title
Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics
Authors
James A. Balogun
Eric Monsalves
Kyle Juraschka
Kashif Parvez
Walter Kucharczyk
Ozgur Mete
Fred Gentili
Gelareh Zadeh
Publication date
01-03-2015
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2015
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-014-9347-2

Other articles of this Issue 1/2015

Endocrine Pathology 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.